Objective: To investigate whether the monoclonal antibody of basic fibroblast growth factor (bFGF-MAb) inhibits the proliferation, invasion and angiogenesis of ovarian cancer.
Methods: 1. Human ovarian cancer cells SKOV3 were planted in 24-well dishes, to which was added bFGF-MAb at different concentrations, and crystal violet staining was performed daily for 8 days, then cell numbers were counted by OD490 determination. 2. SKOV3 were transplanted intraperitoneally to BALB/c nude mice. One week later, bFGF-MAb was injected intraperitoneally twice a week, and the survival time of nude mice, the number and weight of the metastatic tumors on the mensentery were observed or measured. 3. Intratumoral microvessel density(MVD) was measured by immunohistochemical staining for CD31.
Results: 1. bFGF-MAb inhibited the proliferation of SKOV3 in the concentration-dependent manner (P < 0.05). 2. The average survival time of nude mice in bFGF-MAb group increased by 10 days over that of control. 3. The average number and weight of metastatic tumors on mensentery in bFGF-MAb group constituted 70.6% and 69.2% of those in control group, respectively. 4. The MVD in bFGF-MAb group accounted for 62.8% of the MVD in control group.
Conclusion: bFGF-MAb can inhibit the proliferation and angiogenesis of ovarian cancer markedly, so it promises to have application in the biological treatment of ovarian cancer.